Alfonso Rodriguez Espada/LinkedIn
Sep 20, 2025, 16:20
Alfonso Rodriguez Espada Validates FXII as a Safe Antithrombotic Target
Alfonso Rodriguez Espada, Postdoctoral Fellow at BIDMC and Broad Institute of Harvard and MIT, shared a post on LinkedIn:
“We showed that heterozygous rare FXII variant carriers are protected against venous thromboembolism (VTE) using high confidence loss-of-function variants from the UK Biobank and NIH All of Us Program while also showing that these mutations are not associated with bleeding or sepsis as speculated in previous reports. Data was validated in vivo using MGB blood samples and mice to further evaluate thrombin generation/activity. This data further pushes FXII as a potential drug target that could prevent VTE in a safe and effective way!”
Read more here.
Stay updated with Hemostasis Today.
-
Jan 11, 2026, 11:00Benjamin YQ Tan on Impacts of Early Cognitive and Psychological Statuses Post-Stroke
-
Jan 11, 2026, 10:46Salvador Payán Pernía: Leukodepletion Reduces Microplastic Burden in Red Blood Cell Concentrates
-
Jan 11, 2026, 10:36Mariasanta Napolitano on Pregnancy and Delivery Outcomes in Women with Hemophilia
-
Jan 11, 2026, 10:19Quick Explanation of Types of Blood Transfusion from John Amako
-
Jan 11, 2026, 06:18Filippo Cademartiri on Why Vascular Health Is Cognitive Health
-
Jan 11, 2026, 06:01Maira Dastgir N on Cannabis-Induced Ischemic Stroke
-
Jan 11, 2026, 05:51Nishant K Mishra on Preventing Post-Stroke Seizures
-
Jan 11, 2026, 05:41Indunil Karunarathna on CSF Xanthochromia in SAH
-
Jan 11, 2026, 05:22Mitchell Elkind on The New York Times Brain Health Challenge: Food Is Brain Medicine!